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RESPONSE:  APPLYING HIV STRATEGIES TO HEPATITIS 
PREVENTION 
Eric Ennis, director of adult outpatient services for Addiction Research and Treatment Services, University 
of Colorado Health Sciences Center, Denver, led five ARTS clinicians in a roundtable discussion. 
Janelle Blake: In the past year or two, our clients who 
have died were lost to liver diseases and not HIV-related 
diseases. This is a very important article. 
Marla Corwin: It’s written clearly and simply. I feel 
that I could give it directly to clients and say, ‘Read 
this,’ and they would understand what they’re 
reading. 
The HIV analogy 
Eric Ennis: I was struck by the fact that the article sug­
gests the same strategies and techniques that we 
have used for years to counsel HIV-positive clients can 
also be applied to counseling hepatitis C patients and 
for use in prevention. It seems so obvious and yet it 
had never crossed my mind to use HIV prevention 
techniques as hepatitis B and C prevention techniques. 
Corwin: The HIV prevention strategies that we use, 
talking to our clients and screening and education, those 
techniques could be incorporated and applied for free. 
This is the kind of counseling that we already do. 
Ennis: As a general rule, injection drug users who know 
they are infected engage in high-risk drug and sex­
ual activities less frequently than those who are unin­
fected or unaware of their HIV status. In applying this 
to hepatitis C, we could perhaps appeal to our hepa­
titis C-positive clients to reduce these same high-risk 
practices using the same appeals we make to our HIV-
positive clients—to be considerate of others, to not 
spread the virus, respect themselves, respect others.  I 
just never applied this to hepatitis C clients. 12 • SCIENCE & PRACTICE PERSPECTIVES—JULY 2002 
Counseling is 
important 
because of 
clients’ resist­
ance to testing 
and their shock 
when they test 
positive. 
Client resistance 
Ennis: As an administrator, I find this article 
minimizes the importance of client resistance. 
Corwin: The counseling is important because of the 
clients’ resistance to testing and their shock when they 
test positive. They don’t think, ‘Oh my God; I’m going 
to die,’ like they do when they hear they are HIV pos­
itive. But they might think, ‘Oh my gosh; I have a seri­
ous illness.’ They are focused on ‘I have this illness,’ 
so it takes several more sessions to explain, ‘This is 
what it means. Have you come up with questions since 
the last time we talked? What are your concerns? Here, 
I have gathered some information for you to read. It 
might help you formulate some questions.’ 
Olivia Estep:  Where I struggle with my hepatitis C 
clients is getting them the care they need for blood 
work. Even though we have all these resources, they 
still tend to fall through the cracks. 
Daria Leslea: There has been some resistance to that 
initial testing, because it is also our responsibility to 
inform the health department that we have such-and­
such numbers of positive HIV cases and such-and­
such numbers of positive hepatitis cases. I’ve come 
across patients saying they didn’t want to be tested 
because they don’t want this knowledge to be shared. 
We tell hepatitis patients that this information is con­
fidential; we would just like to have some numbers 
about the pathology of a particular disease. I’ve had a 
hard time getting this across to patients. 
Even if you have testing and vaccinations avail­
able for clients, there are still some problems. Some 
clients are concerned about the risks of vaccinations 
and the side effects of medicines, some do not want 
to take the time, others don’t want to know whether 
they have HIV or hepatitis.  Resistance is really high, 
especially in the African-American community and 
males. 
Resource constraints and strategies 
Blake: My understanding is that the insured clients 
are tested for all the hepatitis viruses and given vac­
cinations, but that there isn’t funding available to 
do that for our clients who aren’t insured. 
Leslea: That’s true. Where is the money coming from 
for hepatitis A counseling or vaccinations? It seems to 
me that there should be a protocol, and admission to 
the program would ensure that these things happen. 
Ennis: The article says, ‘Many of these activities (for 
instance, educating the staff about hepatitis) do not 
require additional resources, and some, such as build­
ing linkages to potential affiliate programs, make good 
sense for any organization.’  While that may be true, 
it’s a dismissal of the time and energy it takes to incor­
porate extra things into treatment. Even one addi­
tional risk assessment form adds 10 minutes. We all 
know how hard it is to get done what we currently are 
supposed to do. 
Imagine if we had a half-time nurse whose job it 
was just to meet with new patients, to talk about infec­
tions related to drug use, and to screen them, test them, 
and then offer vaccines. And then if we had the money 
for the nurse and the vaccines, think about the huge 
impact that would have, even if we caught one per­
son a month who hadn’t been vaccinated yet and pre­
vented that person from getting hepatitis C. It would-
n’t cost that much. The funding out there is so piecemeal 
and so small. It’s hard to keep consistent funding. It’s 
hard to implement this kind of prevention activity in 
a consistent, long-term fashion because of the scram­
ble to get the resources. 
Scott Powers: There is an organization not mentioned 
in the article that provides a newsletter that is a 
good resource for clinicians and clients on the subject 
of hepatitis C. It’s the Hep C Connection. Their 
newsletter is available online at no cost at www.hepc­
connection.org.& 